Veronika Zuegel joins DSM Pharmaceutical Products

Dr Zuegel has worked in human resources management and communications for more than two decades

Dr Veronika Zuegel has been appointed Vice President Human Resources & Communications of DSM Pharmaceutical Products, the pharmaceutical contract manufacturing and technology organisation of Royal DSM.

Dr Zuegel is a member of the Management Team and reports to Alexander R Wessels, President and Chief Executive Officer of DSM Pharmaceutical Products. She has worked in human resources management and communications for more than 20 years.

Prior to joining DSM, Dr Zuegel held executive positions in human resources at Constantia Packaging and Alcoa, and was member of the board of McDonald's Central Europe und DO&CO. She earned a PhD in law from the University of Salzburg.

You may also like

Manufacturing

dsm-firmenich initiates patent infringement action

dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology
Manufacturing

DSM and Chromatic 3D Materials partner

The global science-based company active in health, nutrition and materials, has entered a partnership with the 3D-printer developer to introduce thermoset materials for 3D-printing of finished manufactured goods
Manufacturing

DSM Sinochem to boost manufacturing capacity at Dutch plant

Increased production will meet growing demand for sustainable antibiotics, helping tackle Antimicrobial Resistance
Manufacturing

DSM Sinochem Pharmaceuticals celebrates 15 years of green 7-ADCA production

Saving more than lives alone
Manufacturing

Update on SafeBridge potent compound safety certification programme

The programme provides drug innovators with an independent assessment of a manufacturing company’s ability to safely produce potent APIs and drug products
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The impact of API properties on product design

Different properties of active ingredients can affect formulation design and development decisions. Dr Anil Kane, Patheon, and Dr Kai Donsbach, DSM Fine Chemicals Austria, look at some of the key properties
Manufacturing

JLL and Royal DSM create DPx from US$2.6bn joint venture

New global CDMO combines capabilities and expertise of Patheon and DSM Pharmaceutical Products
Subscribe now